Opinions of vascular surgeons and podiatrists in Australia and New Zealand on the use of hyperbaric oxygen therapy for lower limb ulcers

Aaron Drovandi, Malindu E Fernando, Tejas P Singh, Torres Woolley, Jonathan Golledge

INTRODUCTION

Lower limb ulcers, which are usually caused by neuropathy, venous or arterial disease, are an important cause of reduced health-related quality of life, increased risk of amputation and high healthcare costs. Established treatments for lower limb ulcers include compression bandaging, off-loading of high foot pressures and venous or arterial surgery, depending on the etiology of the ulcer. Not infrequently, these treatments fail to heal the ulcer, requiring additional therapies to prevent poor outcomes, such as major amputation. Hyperbaric oxygen therapy (HBOT) is a potential treatment option for lower limb ulcers. It is believed to promote healing by facilitating tissue oxygenation, promoting angiogenesis, and stimulating an effective immune response to aid control of infection. There is, however, ongoing debate on the effectiveness and indications for HBOT in treating lower limb ulcers.

A recent meta-analysis of nine randomized trials reported that HBOT improved the odds of healing lower limb ulcers in people with diabetes. There were however methodological weaknesses identified in most of the trials, such as a lack of sample size calculations and absence of blinding outcome assessments to group allocation. There was also substantial evidence of publication bias.

What is already known about this subject?

- Hyperbaric oxygen therapy (HBOT) is recommended for the treatment of non-healing lower limb ulcers, though the quality of evidence supporting this recommendation is low to moderate, and the opinion of specialists who use this therapy is poorly understood.

What are the new findings?

- Vascular surgeons and podiatrists in Australia and New Zealand indicated that they perceive HBOT as having an infrequent role in the management of non-healing venous, ischemic, and neuropathic ulcers.

How might these results change the focus of research or clinical practice?

- Well-designed clinical trials are needed to provide high-quality evidence to inform on the appropriate use of HBOT for lower limb ulcer management among vascular surgeons and podiatrists.
Emerging technologies, pharmacology and therapeutics

heterogeneity in the findings. There was an uncharacteristically strong benefit of HBOT in one of the included trials and when this trial was removed from analyses this substantially reduced the benefit of HBOT. The most recent randomized trial reported that HBOT did not improve ulcer healing or reduce amputations. The provision of HBOT is expensive, time consuming, inconvenient for patients (especially those living in rural areas), and has reported complications, such as baro-trauma, which must be considered when making decisions about its use. Despite these contrasting findings, current international guidelines recommend the use of HBOT for non-healing lower limb ulcers, while acknowledging that the evidence of benefit is only weak to moderate.

The aim of this study was to obtain opinions from two types of specialists about their use and perceptions of the role of HBOT in treating lower limb ulcers. Vascular surgeons and podiatrists were the specialists selected for this study, since these are two of the main specialties that manage lower limb ulcers, and may refer patients for HBOT in their practice.

PARTICIPANTS AND METHODS

Study design and participant recruitment

This was a cross-sectional study in which an online survey run through SurveyMonkey was distributed to vascular surgeons and podiatrists in Australia and New Zealand between August 2019 and March 2020. In these two countries, HBOT is funded for treating non-healing lower limb ulcers at public hospitals. Multiple organizations expected to have vascular surgeons or podiatrists as members were approached via email and requested to distribute the survey link. The organizations contacted were the Australia and New Zealand Society for Vascular Surgery, Diabetic Foot Australia, the Australian Wound Management Association, the Australian Diabetes Society, the New Zealand Ministry of Health, the Podiatry Board of Australia and Podiatry New Zealand. The initial request was sent in August 2019, with reminder requests sent in December 2019 and February 2020.

Procedure and data items collected

Specialists were first presented with an information and consent screen which outlined the purpose of the survey, including the abstract from a recent meta-analysis examining the efficacy of HBOT for treating lower limb ulcers. After consenting to participate, specialists were asked where their practice was located and their specialty. They were then asked whether they currently used HBOT in the treatment of lower limb ulcers and presented with statements related to their perceived role of HBOT in the treatment of ischemic, neuropathic or venous ulcers, which they rated on 5-point ordinal scales (never, rarely, sometimes, frequently or always). The final questions in the survey related to their access to HBOT facilities, criteria for HBOT therapy and the perceived need for more evidence on HBOT effectiveness. The full survey is shown in online supplementary material. In pilot testing, the survey took less than 5 min to complete. There were no incentives offered for participation.

Data analysis

To be considered a complete survey, specialists must have completed a minimum of the first seven survey questions (online supplementary material). These questions covered their opinion on the treatment role of HBOT for the three ulcer types and whether or not they used HBOT for treating lower limb ulcers in their practice. A descriptive analysis was conducted to determine the characteristics of the participants and sum their responses. The 5-point ordinal scale ratings (never, rarely, sometimes, frequently, always) in response to the statements on perceived HBOT role for each ulcer type were scored as 1–5 respectively. These data were presented as median (IQR) and the responses of vascular surgeons and podiatrists compared using Mann-Whitney U test in SPSS V.25 (IBM).

RESULTS

Participants

A total of 102 survey responses were received from 61 vascular surgeons and 41 podiatrists, with 101 responses from 61 vascular surgeons and 40 podiatrists considered complete. Most specialists were practicing in the states of Queensland (n=41), New South Wales (n=20) or Victoria (n=15). Between one and seven respondents were practicing in each of the other Australian states and territories and 12 specialists (eight vascular surgeons and four podiatrists) were practicing in New Zealand.

Current use of HBOT for lower limb ulcers

Thirty-seven (36.6%) specialists indicated they currently used HBOT for the treatment of lower limb ulcers. The other specialists indicated that they did not feel there was a role for HBOT (n=25; 24.8%), or that they did not have access to HBOT (n=39; 38.6%). Most of those without HBOT access indicated that the resource simply had not been established in their practice setting (n=23; 22.7%), was too expensive (n=6; 5.9%), or was not felt to be beneficial to the hospital (n=4; 4.0%). Responses provided in open-text comment boxes included: ‘Only some patients were able to travel for regular treatment’ (Podiatrist), ‘Not enough evidence to suggest HBOT is effective’ (Podiatrist), ‘None in my town. I do refer the occasional one but most patients not willing to travel’ (Vascular surgeon), and ‘Limited use for the cost’ (Vascular surgeon).

Responses to statements about the role of HBOT for treating different types of ulcers

Only 8 (7.9%), 6 (5.9%) and 2 (2.0%) of the specialists indicated that HBOT ‘frequently’ or ‘always’ had a role in the treatment of ischemic, neuropathic and venous lower limb ulcers, respectively (table 1). In comparison, 43 (42.6%), 27 (26.7%) and 24 (23.8%) specialists...
indicated HBOT ‘sometimes’ had a role in the treatment of ischemic, neuropathic and venous lower limb ulcers, respectively (table 1). The remainder responded that HBOT ‘rarely’ or ‘never’ had a role in treating these ulcers (table 1).

### Comparison of responses between vascular surgeons and podiatrists

Vascular surgeons were significantly less likely than podiatrists to indicate that HBOT frequently or always had a role in the treatment of ischemic, neuropathic and venous lower limb ulcers (p<0.001 for ischemic lower limb ulcers, p=0.004 for neuropathic lower limb ulcers, and p<0.001 for venous lower limb ulcers) (table 1).

<table>
<thead>
<tr>
<th>Statement</th>
<th>Never</th>
<th>Rarely</th>
<th>Sometimes</th>
<th>Frequently</th>
<th>Always</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBOT has a treatment role in ischemic foot ulcers.</td>
<td>13 (13)</td>
<td>37 (37)</td>
<td>43 (43)</td>
<td>7 (7)</td>
<td>1 (1)</td>
<td>3 (2–4)</td>
</tr>
<tr>
<td>HBOT has a treatment role in neuropathic foot ulcers.</td>
<td>24 (24)</td>
<td>44 (44)</td>
<td>27 (27)</td>
<td>5 (5)</td>
<td>1 (1)</td>
<td>2 (1–3)</td>
</tr>
<tr>
<td>HBOT has a treatment role in venous leg ulcers.</td>
<td>29 (29)</td>
<td>46 (46)</td>
<td>24 (24)</td>
<td>1 (1)</td>
<td>1 (1)</td>
<td>2 (1–3)</td>
</tr>
</tbody>
</table>

Data were presented as n (%) and median (IQR).

HBOT, hyperbaric oxygen therapy.

### Criteria for HBOT use

More than half (31; 50.8%) of vascular surgeons compared with only six (15%) podiatrists indicated that they currently used HBOT for treating lower limb ulcers (p<0.001). Vascular surgeons were more likely to have access to and use HBOT, whereas podiatrists felt that it had a stronger role in treatment for any of these ulcer types. Vascular surgeons were more likely to have access to and use HBOT, whereas podiatrists felt that it had a stronger role in treatment.

### Need for further randomized clinical trials

The vast majority of respondents (n=76; 75%) indicated that a large trial was needed to test the efficacy of HBOT in treating lower limb ulcers. The remainders believed that no trial was needed either due to strong evidence for this therapy (n=4; 4.0%), strong evidence against this therapy (n=5; 5.0%), or a belief that HBOT will never be an appropriate therapy (n=3; 3.0%). There were no significant differences in these responses between vascular surgeons and podiatrists.

### DISCUSSION

This study investigated the opinions of vascular surgeons and podiatrists on the use of HBOT for lower limb ulcers. One-third of specialists completing this survey indicated that they actively use HBOT for ischemic, neuropathic, or venous leg ulcers, with few indicating it had a strong role in treatment for any of these ulcer types. Vascular surgeons were more likely to have access to and use HBOT, whereas podiatrists felt that it had a stronger role in treatment. When choosing HBOT as a treatment for these ulcers, a lack of response to other therapies and low TcPO2 were considered key criteria. Most specialists indicated that a large clinical trial was needed to assess the efficacy of HBOT in treating these ulcers. Overall, this study indicates the lack of high-quality evidence which supports the use of HBOT in managing lower limb ulcers, as reflected by the low number of specialists indicating that they use it frequently for ulcer management.

International guidelines refer to several recent reviews and notable randomized controlled trials on HBOT efficacy in ulcer management. A number of these systematic reviews including the most recent have found that HBOT increases the proportion...
Emerging technologies, pharmacology and therapeutics

Table 3  Specialist use of and selection criteria for hyperbaric oxygen therapy

<table>
<thead>
<tr>
<th>Question/statement</th>
<th>Specialist responses</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you currently use HBOT for treating lower limb ulcers?</td>
<td>Vascular surgeons (n=61)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>31 (31)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>30 (30)</td>
</tr>
<tr>
<td>Podiatrists (n=40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>6 (6)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>34 (34)</td>
</tr>
<tr>
<td>If you use HBOT for lower limb ulcers, how do you select patients for treatment? (select all that apply)</td>
<td>Transcutaneous oxygen pressure</td>
<td>19 (51)</td>
</tr>
<tr>
<td></td>
<td>Not suited to other therapies</td>
<td>9 (24)</td>
</tr>
<tr>
<td></td>
<td>Lack of response to other therapies</td>
<td>22 (60)</td>
</tr>
<tr>
<td>I use HBOT for lower limb ulcers based on: (select all that apply)</td>
<td>TcPO2 level less than 20 mm Hg</td>
<td>8 (22)</td>
</tr>
<tr>
<td></td>
<td>TcPO2 level less than 40 mm Hg</td>
<td>12 (32)</td>
</tr>
<tr>
<td></td>
<td>TcPO2 level less than 50 mm Hg</td>
<td>4 (11)</td>
</tr>
<tr>
<td></td>
<td>Not healing after a period of other therapy for 4 weeks</td>
<td>6 (16)</td>
</tr>
<tr>
<td></td>
<td>Not healing after a period of other therapy for 8 weeks</td>
<td>9 (24)</td>
</tr>
<tr>
<td></td>
<td>Not healing after a period of other therapy for 12 weeks</td>
<td>13 (35)</td>
</tr>
<tr>
<td></td>
<td>Not healing after a period of other therapy for 6 months</td>
<td>9 (24)</td>
</tr>
<tr>
<td></td>
<td>Not healing after a period of other therapy for &gt;6 months</td>
<td>10 (27)</td>
</tr>
<tr>
<td></td>
<td>Lack of response to wound debridement</td>
<td>13 (35)</td>
</tr>
<tr>
<td></td>
<td>Lack of response to negative pressure wound therapy</td>
<td>14 (38)</td>
</tr>
<tr>
<td></td>
<td>Lack of response to regular wound dressings</td>
<td>18 (49)</td>
</tr>
<tr>
<td></td>
<td>Lack of response to pressure off-loading</td>
<td>16 (43)</td>
</tr>
<tr>
<td></td>
<td>Lack of response to revascularization</td>
<td>30 (81)</td>
</tr>
<tr>
<td></td>
<td>Oxygen challenge test with increased TcPO2 to &gt;100 mm Hg in the chamber</td>
<td>11 (30)</td>
</tr>
</tbody>
</table>

HBOT, hyperbaric oxygen therapy; TcPO2, transcutaneous oxygen pressure.

of ulcers that completely heal and reduces the incidence of major and minor amputations. Thus, current guidelines recommend HBOT is considered for non-healing lower limb ulcers. It is noted, however, that prior clinical trials have had conflicting findings and methodological shortcomings, highlighting the need for further well-designed trials to provide reliable guidance, which was also indicated by specialists in the current survey. Most of the current guidelines recommend HBOT for ulcer healing either in conjunction with standard therapy, or only when standard therapy has failed to heal the ulcer in a reasonable amount of time, which in most trials is considered as after 4 weeks of therapy. Vascular surgeons and podiatrists in this study reported that these were the directions that they most frequently followed when using HBOT. They indicated that they also considered HBOT when patients were not eligible for standard therapy and also used TcPO2 to guide use of HBOT, which is not listed in current guidelines.

The reasons behind the variation between vascular surgeon and podiatrist in the use of HBOT and opinions about the value of HBOT in ulcer healing identified in this study are not certain. Vascular surgeons typically work in tertiary hospitals where HBOT facilities are usually located, making it likely they have greater access to refer patients for this therapy than podiatrists, who more frequently work in community clinics. This may explain why vascular surgeons more frequently indicated that they refer patients for HBOT than podiatrists, despite their opinions of it having a less frequent place in therapy. The reasons for this difference in opinions on the treatment role of HBOT may be due to variations in professional guidelines, reflecting ulcer etiology commonly managed by these specialists. The current international guideline published for vascular surgeons states that there is ongoing controversy about the value of HBOT for treating lower limb ulcers. The guidelines state that there may be a role for the use of HBOT to accelerate ulcer healing in people with diabetes with non-healing neuropathic ulcers and low-grade ischemia. This is in comparison to multiple Australian guidelines used by podiatrists, which appear to be more supportive for the use of HBOT, stating it may be considered as part of a comprehensive wound management program.
As a result of the aforementioned shortcomings in previous research, there is widespread consensus on the need for further research investigating the benefit (if any) of HBOT in ulcer healing, which was indicated by the majority of vascular surgeons and podiatrists in this study. This further research in the form of a well-powered randomized controlled trial would need to demonstrate a clear benefit of HBOT in ulcer wound healing through a methodologically sound approach that avoids shortcomings demonstrated in previous research. The outcomes of such a trial would inform guideline recommendations to direct a range of relevant health professionals, including vascular surgeons and podiatrists, on the appropriateness and efficacy of HBOT in lower limb ulcer management.

The current study has a number of limitations that should be acknowledged. As the surveys were sent out to practitioners via professional societies, it was not possible to calculate the response rate. It is therefore unclear how representative the opinions obtained were of the overall community of vascular surgeons and podiatrists in Australia and New Zealand. Also, only two types of specialists who may refer patients for HBOT were included in this survey. Their opinions may differ from other relevant specialists, such as general practitioners, nurses and hyperbaric oxygen specialists. Lastly, only specialists from two countries were included in this survey. Their opinions may differ from specialists in other countries.

In conclusion, this survey suggests that approximately one-third of Australia and New Zealand vascular surgeons and podiatrists use HBOT in treating lower limb ulcers. These specialists mostly felt that HBOT only sometimes had a role in treating ischemic, neuropathic, or venous lower limb ulcers. A majority of specialists indicated that further high-quality research was needed to guide the use of this therapy and determine its effectiveness for ulcer management.

Author affiliations
1 Queensland Research Centre for Peripheral Vascular Disease, James Cook University College of Medicine and Dentistry, Townsville, Townsville, Queensland, Australia
2 College of Medicine and Dentistry, James Cook University Division of Tropical Health and Medicine, Townsville, Queensland, Australia
3 Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, Queensland, Australia

Acknowledgements The authors thank the participating vascular surgeons and podiatrists and the professional organizations who assisted in the completion of this survey.

Contributors JG takes responsibility for the integrity of the work as a whole, from inception to published article. JG and TPS designed the research study. JG, TPS, MEF, and TW designed the survey tool. JG, MEF, and AD collected and analyzed the data. JG, MEF, and AD wrote the manuscript, with all authors editing and approving the final manuscript version.

Funding Funding from The Townsville Hospital and Health Services Study, Education and Research Trust Fund, James Cook University (Strategic Research Investment Fund) and Queensland Government supported this work. JG holds a Practitioner Fellowship from the National Health and Medical Research Council (1117061) and a Senior Clinical Research Fellowship from the Queensland Government, Australia.

REFERENCES

Disclaimer The funders played no role in study design, conduct, data collection, analysis and interpretation, and did not assist in preparation or review of this manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study received an ethics waiver from the Townsville Hospital and Health Service Human Research Ethics Committee (LNR/2019/0THS/54813). Ethics waivers are available for clinical audits and quality improvement or assurance research activities that are considered as being of low or negligible risk.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request to the authors.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Aaron Drovandi http://orcid.org/0000-0002-8682-1218
Jonathan Golledge http://orcid.org/0000-0002-5779-8848

BMJ Open Diab Res Care: first published as 10.1136/bmjdrcc-2020-001590 on 2 August 2020. Downloaded from http://drc.bmj.com/ on September 14, 2023 by guest. Protected by copyright.
Emerging technologies, pharmacology and therapeutics